Experian


Healthy H1 FY20/21 performance; momentum to sustain during Q3 FY20/21

18/11/20 -"Experian performed strongly in Q2 FY20/21 (+5% yoy organic revenue; at top-end of management’s guidance), on the back of the sustained robust momentum in the US mortgage activity and consumer ..."

Pages
52
Language
English
Published on
18/11/20
You may also be interested by these reports :
11/03/26
The adjustment of the target price reflects the update of our model (see comments on EPS and NAV). The company remains solid and achieved its ...

09/03/26
We remain positive on Bilfinger, as its business model is light on fixed assets, and more than 80% of revenue is recurring, which should provide a ...

05/03/26
Rentokil Initial reported H2 results in line with market expectations for sales, EBIT, and EPS. North America continues to show signs of ...

04/03/26
Bilfinger’s full-year results for 2025 exceeded expectations in ways that merit closer examination. Free cash flow surged 75% to €330 million, the ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO